Puluo Pharmaceutical Co., Ltd. signed a technical cooperation development contract with West China Hospital of Sichuan University on "targeted histone modified new antitumor drugs"

In order to promote the development of the company in the field of anti-cancer and support the "major science and technology projects for new drug creation" of the state, PLO pharmaceutical announced in the evening of March 18 Recently, the company signed a "strategic cooperation framework agreement" with Sichuan University and a technical cooperation development contract with West China Hospital of Sichuan University for "targeted histone modified new anti-tumor drugs" According to reports, "targeted histone modified anti-tumor new drugs" belong to the national key research and development field, the field of epigenetics related new drugs According to the data, the State Key Laboratory of biotherapy of Sichuan University is the national comprehensive platform for innovative drug research and development led by Wei Yuquan, academician of the Chinese Academy of Sciences, and the biotherapy collaborative innovation center of the Ministry of education At present, a series of key technology platforms have been established, from gene discovery to drug research and development and clinical treatment, such as key technology platforms for drug research and development such as biotechnology drugs and gene therapy; the national pre clinical evaluation center for new drugs and the national clinical trial base for new drugs (biotherapy), etc PLO pharmaceutical said that this cooperation is mainly for the company to make better use of the advantages of universities and enterprises in human resources, scientific research, industrialization and commercialization, enhance the company's core competitiveness and independent innovation ability in the field of anti-tumor, and actively explore new models and mechanisms of school enterprise cooperation and innovation.